Actimab-A: Interim Phase I/II data

Interim data from 9 evaluable AML patients ages =60 in an open-label, U.S. Phase

Read the full 142 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE